Photodiagnosis and Photodynamic Therapy
Volume 3, Issue 1 , Pages 27-33 , March 2006

The effect of dimethylsulfoxide, 1-[2-(decylthio)ethyl]azacyclopentan-2-one and Labrafac®CC on porphyrin formation in normal mouse skin during topical application of methyl 5-aminolevulinate: A fluorescence and extraction study

  • Andrzej Bugaj, Master of Pharmacy, PhD

      Affiliations

    • Department of Clinical Pharmacy and of Biopharmacy, Karol Marcinkowski University of Medical Sciences, 61-861 Poznań, Poland
    • Department of Radiation Biology, Institute for Cancer Research, The Norwegian Radium Hospital, 0310 Oslo, Norway
    • Corresponding Author InformationCorresponding author. Tel.: +4861 8529057x54; fax: +4861 8529057x55.
    • ,
  • Vladimir Iani

      Affiliations

    • Department of Radiation Biology, Institute for Cancer Research, The Norwegian Radium Hospital, 0310 Oslo, Norway
    • ,
  • Asta Juzeniene

      Affiliations

    • Department of Radiation Biology, Institute for Cancer Research, The Norwegian Radium Hospital, 0310 Oslo, Norway
    • ,
  • Petras Juzenas

      Affiliations

    • Department of Radiation Biology, Institute for Cancer Research, The Norwegian Radium Hospital, 0310 Oslo, Norway
    • ,
  • Li-Wei Ma

      Affiliations

    • Department of Radiation Biology, Institute for Cancer Research, The Norwegian Radium Hospital, 0310 Oslo, Norway
    • ,
  • Johan Moan

      Affiliations

    • Department of Radiation Biology, Institute for Cancer Research, The Norwegian Radium Hospital, 0310 Oslo, Norway
    • Institute of Physics, Oslo University, 0316 Oslo, Norway

References 

  1. Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B. 1990;6:143–148
  2. Kelty CJ, Brown NJ, Reed MWR, Ackroyd R. The use of 5-aminolaevulinic acid as a photosensitizer in photodynamic therapy and photodiagnosis. Photochem Photobiol Sci. 2002;3:158–168
  3. Smith RP. Photodynamic therapy. Curr Probl Cancer. 2002;26:67–108
  4. Ormrod D, Jarvis B. Topical aminolevulinic acid HCl photodynamic therapy. Am J Clin Dermatol. 2000;103:133–139
  5. Gay CL, Guy RH, Golden GM, Mak VHW, Francoeur ML. Characterization of low temperature (i.e. <65°C) lipid transitions in human stratum corneum. J Invest Dermatol. 1994;103:233–239
  6. Kloek J, Beijersbergen van Henegouven GMJ. Prodrugs of 5-aminolevulinic acid for photodynamic therapy. Photochem Photobiol. 1996;64:994–1000
  7. Peng Q, Moan J, Warloe T, et al. Build-up of esterified aminolevulinic-acid-derivative-induced porphyrin fluorescence in normal mouse skin. J Photochem Photobiol B. 1996;34:95–96
  8. Casas A, Batlle A. Rational design of 5-aminolevulinic acid derivatives aimed at improving photodynamic therapy. Curr Med Chem. 2002;2:465–475
  9. Tarstedt M, Rosdahl I, Berne B, Svanberg K, Wennberg AM. A randomized multicenter study to compare two treatment regimens of topical methyl aminolevulinate (Metvix®)-PDT in actinic keratosis of the face and scalp. Acta Derm Venereol. 2005;85:424–428
  10. Turchiello RF, Vena FC, Maillard P, Souza CS, Bentley MVLB, Tedesco AC. Cubic phase gel as a drug delivery system for topical application of 5-ALA, its ester derivatives and m-THPC in photodynamic therapy (PDT). J Photochem Photobiol B. 2003;70:1–6
  11. Casas A, Perotti C, Saccoliti M, Sacca P, Fukuda H, Batlle AMC. ALA and ALA hexyl ester in free and liposomal formulations for the photosensitisation of tumour organ cultures. Br J Cancer. 2002;86:837–842
  12. Merclin N, Bender J, Sparr E, Guy RH, Ehrsson H, Engstrom S. Transdermal delivery from a lipid sponge phase – iontophoretic and passive transport in vitro of 5-aminolevulinic acid and its methyl ester. J Control Release. 2004;100:191–198
  13. Lopez RFV, Bentley MVLB, Delgado-Charro D, van den Salomon BH, Lange N, Guy RH. Enhanced delivery of 5-aminolevulinic acid esters by iontophoresis in vitro. Photochem Photobiol. 2003;77:304–308
  14. Casas A, Batlle AMC. Rational design of 5-aminolevulinic acid derivatives aimed as at improving photodynamic therapy. Curr Med Chem Anti-Canc Agents. 2002;2:465–475
  15. Ziólkowski P, Osiecka BJ, Oremek G, et al. Enhancement of photodynamic therapy by use of aminolevulinic acid/glycolic acid drug mixture. J Exp Ther Oncol. 2004;4:121–129
  16. Harth Y, Hirshowitz B, Kaplan B. Modified topical photodynamic therapy of superficial skin tumours, utilizing aminolevulinic acid, penetration enhancers, red light and hyperthermia. Dermatol Surg. 1998;24:723–726
  17. Casas A, Fukuda H, Di Venosa G, Batlle AMC. The influence of the vehicle on the synthesis of porphyrins after topical application of 5-aminolaevulinic acid. Br J Dermatol. 2000;143:564–572
  18. de Rosa FS, Marchetti JM, Thomazini JA, Tedesco AC, Bentley MVLB. A vehicle for photodynamic therapy of skin cancer: influence of dimethylsulphoxide on 5-aminolevulinic acid in vitro cutaneous permeation and in vivo protoporphyrin IX accumulation determined by confocal microscopy. J Control Release. 2000;65:359–366
  19. van den Akker JT, Iani V, Star WM, Sterenborg HJCM, Moan J. Topical application of 5-aminolevulinic acid hexyl ester and 5-aminolevulinic acid to normal nude mouse skin: differences in protoporphyrin IX fluorescence kinetics and the role of the stratum corneum. Photochem Photobiol. 2000;72:681–689
  20. Perotti C, Casas A, Fukuda H, Sacca P, Batlle AMC. Topical application of ALA and ALA hexyl ester on a subcutaneous murine mammary adenocarcinoma: tissue distribution. Br J Cancer. 2003;88:432–437
  21. Juzeniene A, Juzenas P, Iani V, Moan J. Topical application of 5-aminolevulinic acid and its methylester, hexylester and octylester derivatives: considerations for dosimetry in mouse skin model. Photochem Photobiol. 2002;76:329–334
  22. Gomer ChJ, Jester JV, Razum NJ, Szirth BC, Murphree AL. Photodynamic therapy of intraocular tumors examination of hematoporphyrin derivative distribution and long-term damage in rabbit ocular tissue. Cancer Res. 1985;45:3718–3725
  23. van den Akker J, Iani V, Star W, Sterenborg HJCM, Moan J. Systemic component of protoporphyrin IX production in nude mouse skin upon topical application of aminolevulinic acid depends on the application conditions. Photochem Photobiol. 2001;75:172–177
  24. Moan J, Ma LW, Juzeniene A, et al. Pharmacology of protoporphyrin IX in nude mice after application of ALA and ALA esters. Int J Cancer. 2003;103:132–135
  25. de Rosa FS, Lopez RFV, Thomazini JS, Tedesco AC, Lange N, Bentley MVLB. In vitro metabolism of 5-ALA esters derivatives in hairless mice skin homogenate and in vivo PPIX accumulation studies. Pharm Res. 2004;21:2247–2252
  26. Casas A, Perotti C, Fukuda H, Rogers L, Butler AR, Batlle AMC. ALA and ALA hexyl ester induced porphyrin synthesis in chemically induced skin tumors: the role of different vehicles on improving photosensitization. Br J Cancer. 2001;85:1794–1800
  27. Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev. 2004;56:603–618
  28. Galbraith RA, Sassa S, Fujita H. Regulation of heme synthesis in HepG2 human hepatoma cells by dimethyl sulfoxide. Biochem Biophys Res Commun. 1988;16:869–874
  29. Yano T, Furukawa K, Tsuji M, Noda K, Otagiri M. Evaluation of a new penetration enhancer 1-[2-(decylthio)ethyl]azacyclopentan-2-one (HPE-101). J Pharmacobiodyn. 1992;15:527–533
  30. Yano T, Higo N, Fukuda K, Tsuji M, Noda K, Otagiri M. Further evaluation of a new penetration enhancer, HPE-101. J Pharm Pharmacol. 1993;45:775–778
  31. Hadgraft J, Walters KA, Guy RH. Epidermal lipids and topical drug delivery. Semin Dermatol. 1992;11:139–144
  32. Kim HJ, Yoon KA, Hahn M, Park ES, Chi SC. Preparation and in vitro evaluation of self-microemulsifying drug delivery systems containing idebenone. Drug Dev Ind Pharm. 2000;26:523–529
  33. Kommuru TR, Gurley B, Khan MA, Reddy IK. Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: formulation, development and bioavailability assessment. Int J Pharm. 2001;212:233–246
  34. Minkov I, Ivanova T, Panaiotov I, Proust J, Saulnier P. Reorganization of lipid nanocapsules at air–water interface: Part 2. Properties of the formed surface film. Drug Dev Ind Pharm B Biointerfaces. 2005;44:197–203
  35. Minkov I, Ivanova T, Panaiotov I, Proust J, Verger R. Reorganization of lipid nanocapsules at air–water interface: Part 3. Action of hydrolytic enzymes HLL and pancreatic PLA(2). Colloids Surf B Biointerfaces. 2005;45:24–34
  36. Strickley RG. Solubilizing excipients in oral and injectable formulations. Pharm Res. 2004;21:201–230
  37. Steluti R, De Rosa FS, Collett JH, Bentley MVLB. In vitro skin retention and permeation studies for 5-aminolevulinic acid: effect of a lipid penetration enhancer. Eur J Pharm. 2001;1001:S23–S166
  38. Aungst BJ, Rogers NJ, Shefter E. Enhancement of naloxone penetration through human skin in vitro using fatty acids, fatty alcohols, surfactants, sulfoxides and amides. Int J Pharm. 1986;33:225–234
  39. Aungst BJ. Structure–effects studies of fatty acid isomers as skin penetration enhancers and skin irritants. Pharm Res. 1989;6:244–247
  40. Jungbauer FHW, Coenraads PJ, Kardaun SH. Toxic hygroscopic contact reaction to N-methyl-2-pyrrolidone. Contact Dermat. 2001;45:303–304

PII: S1572-1000(05)00109-2

doi: 10.1016/S1572-1000(05)00109-2

Photodiagnosis and Photodynamic Therapy
Volume 3, Issue 1 , Pages 27-33 , March 2006

Article Tools

* Image Usage & Resolution